BioMarin Pharmaceutical (BMRN) Competitors $59.67 +2.85 (+5.02%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. ALNY, BIIB, UTHR, INCY, EXEL, NBIX, EXAS, HALO, MDGL, and RGENShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Exelixis Neurocrine Biosciences Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do analysts prefer BMRN or ALNY? BioMarin Pharmaceutical presently has a consensus price target of $94.00, suggesting a potential upside of 57.53%. Alnylam Pharmaceuticals has a consensus price target of $315.58, suggesting a potential upside of 31.49%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.71Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Do institutionals and insiders hold more shares of BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 15 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 10 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.95 beat Alnylam Pharmaceuticals' score of 0.84 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor BMRN or ALNY? BioMarin Pharmaceutical received 416 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.59% of users gave BioMarin Pharmaceutical an outperform vote. CompanyUnderperformOutperformBioMarin PharmaceuticalOutperform Votes157974.59% Underperform Votes53825.41% Alnylam PharmaceuticalsOutperform Votes116376.31% Underperform Votes36123.69% Which has more risk & volatility, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Which has preferable earnings and valuation, BMRN or ALNY? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$2.85B3.99$167.65M$2.2027.12Alnylam Pharmaceuticals$2.25B13.89-$278.16M-$2.17-110.60 Is BMRN or ALNY more profitable? BioMarin Pharmaceutical has a net margin of 14.96% compared to Alnylam Pharmaceuticals' net margin of -12.37%. BioMarin Pharmaceutical's return on equity of 9.91% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical14.96% 9.91% 7.65% Alnylam Pharmaceuticals -12.37%N/A -6.83% SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Remove Ads Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.38B$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio27.126.7721.7517.78Price / Sales3.99228.59380.5194.51Price / Cash21.1765.6738.1534.64Price / Book2.015.886.433.99Net Income$167.65M$141.32M$3.20B$247.24M7 Day Performance6.76%8.48%9.08%8.29%1 Month Performance-14.07%-12.84%-6.04%-5.37%1 Year Performance-34.79%-12.40%10.66%-0.24% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.8914 of 5 stars$59.67+5.0%$94.00+57.5%-35.3%$11.38B$2.85B27.123,401Gap UpALNYAlnylam Pharmaceuticals4.5031 of 5 stars$232.95-1.2%$316.25+35.8%+61.6%$30.67B$2.25B-107.352,000BIIBBiogen4.6979 of 5 stars$119.19-3.1%$213.33+79.0%-39.8%$17.45B$9.68B10.658,720UTHRUnited Therapeutics4.9044 of 5 stars$291.72-0.3%$388.25+33.1%+22.2%$13.10B$2.88B12.81980Positive NewsINCYIncyte4.8353 of 5 stars$60.29-0.5%$74.88+24.2%+10.0%$11.67B$4.24B223.302,320EXELExelixis4.256 of 5 stars$34.84+0.8%$37.59+7.9%+56.7%$9.75B$2.17B19.681,220Positive NewsGap DownNBIXNeurocrine Biosciences4.8404 of 5 stars$93.25-2.5%$163.52+75.4%-29.5%$9.30B$2.36B28.341,200Analyst UpgradeNews CoveragePositive NewsGap UpHigh Trading VolumeEXASExact Sciences4.2313 of 5 stars$43.83+3.0%$70.26+60.3%-38.0%$8.14B$2.76B-7.876,400High Trading VolumeHALOHalozyme Therapeutics4.3931 of 5 stars$59.35-0.7%$62.78+5.8%+59.0%$7.33B$1.02B17.30390Positive NewsMDGLMadrigal Pharmaceuticals4.0512 of 5 stars$310.52-1.2%$378.44+21.9%+36.2%$6.94B$180.13M-12.3890News CoveragePositive NewsGap UpRGENRepligen4.7469 of 5 stars$116.11+3.7%$178.64+53.9%-25.8%$6.52B$634.44M-227.672,020Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors EXEL Competitors NBIX Competitors EXAS Competitors HALO Competitors MDGL Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMRN Stock Free BMRN Stock Alerts